Show simple item record

dc.creatorAnikpo, Ifedioranma
dc.creatorAgovi, Afiba Manza-A.
dc.creatorCvitanovich, Matthew J.
dc.creatorLonergan, Frank
dc.creatorJohnson, Marc
dc.creatorOjha, Rohit P.
dc.date.accessioned2022-01-26T14:35:08Z
dc.date.available2022-01-26T14:35:08Z
dc.date.issued2021
dc.identifier.urihttps://doi.org/10.1111/hiv.13147
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/hiv.13147
dc.identifier.urihttps://repository.tcu.edu/handle/116099117/49913
dc.description.abstractObjectives Little is known about the external validity of the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) model for predicting cardiovascular disease (CVD) risk among people living with HIV (PLWH). We aimed to evaluate the performance of the updated D:A:D model for 5-year CVD risk in a diverse group of PLWH engaged in HIV care. Methods We used data from an institutional HIV registry, which includes PLWH engaged in care at a safety-net HIV clinic. Eligible individuals had a baseline clinical encounter between 1 January 2013 and 31 December 2014, with follow-up through to 31 December 2019. We estimated 5-year predicted risks of CVD as a function of the prognostic index and baseline survival of the D:A:D model, which were used to assess model discrimination (C-index), calibration and net benefit. Results Our evaluable population comprised 1029 PLWH, of whom 30% were female, 50% were non-Hispanic black, and median age was 45 years. The C-index was 0.70 [95% confidence limits (CL): 0.64-0.75]. The predicted 5-year CVD risk was 3.0% and the observed 5-year risk was 8.9% (expected/observed ratio = 0.33, 95% CL: 0.26-0.54). The model had a greater net benefit than treating all or treating none at a risk threshold of 10%. Conclusions The D:A:D model was miscalibrated for CVD risk among PLWH engaged in HIV care at an urban safety-net HIV clinic, which may be related to differences in case-mix and baseline CVD risk. Nevertheless, the HIV D:A:D model may be useful for decisions about CVD intervention for high-risk patients.
dc.language.isoenen_US
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceHIV Medicine
dc.subjectcardiovascular disease
dc.subjectclinical epidemiology
dc.subjectexternal validation
dc.subjectHIV
dc.subjectprediction model
dc.titleThe data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV
dc.typeArticle
dc.rights.holderThe authors
dc.rights.licenseCC BY-NC 4.0
local.collegeBurnett School of Medicine
local.departmentBurnett School of Medicine
local.personsAgovi, Ojha (SOM)


Files in this item

Thumbnail
Thumbnail
This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/